While GH has been patented as a potential therapeutic to increase corneal epithelial wound closure [111], prospective clinical trials are needed to assess potential therapeutic benefits of topical GH application on corneal epithelial regeneration and stromal haze development in human clinical populations, particularly in cohorts presenting with persistent corneal epithelial defects due to infection or limbal cell deficiencies. This evidence concerns the gene GH1 and infection.